Argenica Therapeutics (AGN) H2 2026 earnings summary

Executive summary

• Revenue increased 53% year-over-year to $5.7 million, driven by higher R&D tax incentives and government grants.

• Net loss after tax decreased 81% year-over-year to $1.37 million, reflecting lower R&D expenses and increased non-dilutive funding.

• No dividends were declared for the year.

• The company completed a pivotal Phase 2 trial for xaranetide in acute ischaemic stroke, meeting safety endpoints and showing efficacy in severe cases.

• Preparation for a late-stage (Phase 2b/3) trial is underway, with protocol design leveraging AI-enabled diagnostics.

Financial highlights

• Revenue: $5,696,563 (up 53% year-over-year).

• Net loss after tax: $(1,365,362), down from $(7,170,347) in the prior year.

• R&D tax incentive rebate: $3,974,974 (prior year: $2,757,459).

• Government grant income: $1,509,574 (prior year: $424,289).

• Research and development costs: $4,209,047 (prior year: $8,132,295).

• Net operating cash outflows: $4,189,674 (prior year: $5,704,397).

• Cash and cash equivalents at year-end: $6,362,541.

Outlook and guidance

• The company is advancing a targeted late-stage clinical trial for xaranetide in stroke, with plans to submit an IND response to the FDA.

• Manufacturing scale-up and regulatory preparations are ongoing to support future clinical and commercial activities.

• Further development in traumatic brain injury and concussion indications is under consideration.